[go: up one dir, main page]

Rene et al., 2010 - Google Patents

Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity

Rene et al., 2010

View PDF
Document ID
10012945085760866514
Author
Rene P
Le Gouill C
Pogozheva I
Lee G
Mosberg H
Farooqi I
Valenzano K
Bouvier M
Publication year
Publication venue
The Journal of pharmacology and experimental therapeutics

External Links

Snippet

Heterozygous null mutations in the melanocortin-4 receptor (MC4R) cause early-onset obesity in humans, indicating that metabolic homeostasis is sensitive to quantitative variation in MC4R function. Most of the obesity-causing MC4R mutations functionally …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/566—Immunoassay; Biospecific binding assay using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Similar Documents

Publication Publication Date Title
Rene et al. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity
CA2930810C (en) Pharmacological chaperones for treating obesity
Ersoy et al. Mechanism of N-terminal modulation of activity at the melanocortin-4 receptor GPCR
van der Velden et al. Perspective: implications of ligand–receptor binding kinetics for therapeutic targeting of G protein-coupled receptors
Chen et al. Identification of serine 348 on the apelin receptor as a novel regulatory phosphorylation site in apelin-13-induced G protein-independent biased signaling
Noorwez et al. A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin
Deml et al. Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor
Sensi et al. Oxysterols act as promiscuous ligands of class-A GPCRs: in silico molecular modeling and in vitro validation
Wang et al. Rescue of defective MC4R cell-surface expression and signaling by a novel pharmacoperone Ipsen 17
Rahman et al. Evaluation of amide bioisosteres leading to 1, 2, 3-triazole containing compounds as GPR88 agonists: design, synthesis, and structure–activity relationship studies
Bumbak et al. Conformational changes in tyrosine 11 of neurotensin are required to activate the neurotensin receptor 1
Han et al. Characterization of G protein coupling mediated by the conserved D1343. 49 of DRY motif, M2416. 34, and F2516. 44 residues on human CXCR1
Saitoh et al. The present and future of synthetic orexin receptor agonists
Peri et al. A bitter anti-inflammatory drug binds at two distinct sites of a human bitter taste GPCR
Colson et al. A hydrophobic cluster between transmembrane helices 5 and 6 constrains the thyrotropin-releasing hormone receptor in an inactive conformation
Adams et al. Development of ProTx-II analogues as highly selective peptide blockers of Nav1. 7 for the treatment of pain
Guan et al. Indole-containing amidinohydrazones as nonpeptide, dual RXFP3/4 agonists: synthesis, structure–activity relationship, and molecular modeling studies
Hogan et al. Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3. 28 (125), I3. 32 (129), and I7. 42 (291) is critical for receptor activation
Kaiser et al. Biased agonists at the human Y1 receptor lead to prolonged membrane residency and extended receptor G protein interaction
Toth et al. Encoding the β-arrestin trafficking fate of ghrelin receptor GHSR1a: C-tail-independent molecular determinants in GPCRs
Desai et al. Molecular mechanism of action of triazolobenzodiazepinone agonists of the type 1 cholecystokinin receptor. Possible cooperativity across the receptor homodimeric complex
Manfra et al. Downregulation of 5-HT7 serotonin receptors by the atypical antipsychotics clozapine and olanzapine. Role of motifs in the C-terminal domain and interaction with GASP-1
JPH11507518A (en) Functional bioassay for agonists and antagonists of receptors coupled to G proteins
Heller et al. Novel probes establish Mas-related G protein-coupled receptor X1 variants as receptors with loss or gain of function
Florén et al. Multiple interaction sites of galnon trigger its biological effects